A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-16

Study Completion Date

2025-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.

The participants will be treated with TAK-625 for up to the end of study (about 34 months).

Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

NCT01422187

Gaucher Disease

COMPLETED PHASE3

A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

NCT01132690

Gaucher Disease

COMPLETED PHASE4

Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

NCT06114329

Fabry Disease

RECRUITING PHASE2

A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

NCT01411228

Gaucher Disease

COMPLETED PHASE3

A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia

NCT04117880

Aniridia

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alagille Syndrome (ALGS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAK-625

TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.

Group Type EXPERIMENTAL

TAK-625

Intervention Type DRUG

TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-625

TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Maralixibat chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant is Japanese male or female with a body weight \>=3.0 kilograms (kg) and who is \>=1 month of age at the time of informed consent.
2. The participant is diagnosed with ALGS.
3. The participant has one or more of the following evidences of cholestasis:

1. Total serum bile acid (sBA) \>3\^ upper limit of the normal range (ULN) for age.
2. Direct bilirubin (conjugated) \>1 mg/dL.
3. Lipid soluble vitamin (LSV) deficiency otherwise unexplainable.
4. Gamma-glutamyl transferase (GGT) \>3\^ ULN for age.
5. Intractable pruritus explainable only by liver disease.
4. The participant is expected to have a consistent caregiver(s) for the duration of the study.
5. The participant has an access to phone for scheduled calls from study site.
6. Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
7. Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
8. Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the participant is an adult (over 18 years old).
9. Average daily score \>2 on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, participants \<12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.

Exclusion Criteria

1. The participant has chronic diarrhea requiring ongoing intravenous (IV) fluid or nutritional intervention.
2. The participant has a previous history of surgical interruption of the enterohepatic circulation.
3. The participant has a previous liver transplant.
4. The participant decompensated cirrhosis (ALT \>15\^ ULN, international normalized ratio \[INR\] \>1.5 \[unresponsive to vitamin K therapy\], albumin \<3.0 g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
5. The participant has a history or presence of other concomitant liver disease.
6. The participant has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
7. The participant has a history or presence of gallstones or kidney stones.
8. The participant has a possible malignant liver mass in imaging, including screening ultrasound.
9. The participant has cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
10. The participant has received bile acid/lipid binding resins or IBAT inhibitors within 28 days prior to screening and throughout the trial.
11. The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.

Minimum Eligible Age

1 Month

Eligible Sex

ALL

Accepts Healthy Volunteers

No